Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal and Intravenous Nab-paclitaxel Plus S-1 for Gastric Cancer with Peritoneal Metastasis and Malignant Ascites
ChiCTR2000036223Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel and tegafur in gastric adenocarcinoma, gastric cancer (GC), peritoneal carcinomatosis (PC) and 1 more, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoints: Objective remission rate of ascites, Objective remission rate of tumour and 1 more. Started Aug 2020; status: recruiting.
02
Drugs
paclitaxeltegafur
03
Conditions
gastric adenocarcinomagastric cancer (GC)peritoneal carcinomatosis (PC)malignant ascites
Beyond the preview
Go deeper on ChiCTR2000036223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036223.